攜手共創新局

我們擁有 College of American Pathologists (CAP) 認可的實驗室，並提供廣泛的檢測服務以支持全球各地的臨床試驗。

Our Value Proposition

高成功率

通過持續優化實驗室協議，我們以有限的樣本獲得卓越的結果。

專為亞洲基因量身定制

我們通過定期更新的數據庫，以重點為亞洲人提供相關的臨床應用。Find out more about our studies.

及時、持續的支援

提供測試諮詢提供快速的報告、提供一對一報告諮詢，支援第一線癌症治療計畫與決策。

值得信賴的品牌

受到國際認可，並由主要癌症醫院和診所參與。

我們聚焦於

臨床級 NGS

我們提供 NGS 服務平台，可從最小的腫瘤樣本精確檢測癌症變體。我們為各種樣本類型提供具有生物信息學分析專業知識的解決方案，整合公共和專有數據庫，以提供全面且易於理解的醫療報告。

臨床試驗支援

憑藉認證的平台和不斷開發新興生物標記的服務，我們作為生物製藥合作夥伴，為生物標記驅動的試驗提供定制解決方案。我們與超過 200 多個亞洲醫院合作，我們能夠通過最大限度地利用基因定序來加速您的臨床試驗。

中央實驗室服務及實驗室認證

我們在台灣和香港的實驗室以及日本的合資實驗室獲得美國病理學學院（CAP）的認證；我們在運營、服務和當地提供客製服務，滿足您的特定需求。

Flexible & Collaborative Partnerships

We offer tailored collaboration models across sponsor-initiated studies, investigator-initiated trials (IITs), registry studies, and early- to post-marketing programs, backed by reliable execution and a strong commitment to quality.

我們的檢測

謝謝！您的提交已收到！

抱歉！提交表格時出現問題。

Treatment

OncoOmicsDx™ Clinical Tumor Proteomics Test utilizes an advanced high-throughput mass spectrometry platform combined with proprietary targeted proteomics technology to perform absolute quantification of key tumor-associated proteins. Each test can simultaneously measure the expression levels of up to 30 or 72 tumor biomarker proteins, delivering high-resolution protein expression data for patients with solid tumors.

Treatment

ACT Nonet™ is an RT-PCR customizable tissue panel. It covers 167 variants of 11 genes with U.S. FDA-approved targeted treatments. Including all NCCN guideline-recommended genes and high sensitivity (1~5% of DNA, 125 copies/reaction for RNA).

藥物治療選擇

ACTDrug® GI is an NGS‑based test that detects 20 clinically actionable genes in gastrointestinal cancer-tumor tissue. These genes align with FDA‑approved and NCCN-guideline-recommended targeted therapies, supporting timely and informed treatment decisions.

藥物治療選擇

ACTDrug® Breast is an NGS‑based test that detects 16 clinically actionable genes in breast tumor tissue. These genes align with FDA‑approved and NCCN-guideline-recommended targeted therapies, supporting timely and informed treatment decisions.

藥物治療選擇

ACTDrug®+ is an NGS‑based test that profiles 101 genes to detect clinically relevant gene alterations aligned with FDA‑approved and NCCN guideline‑recommended targeted therapies, supporting timely treatment decisions.

藥物治療選擇